Vivimed Labs (NSE:VIVIMEDLAB) Cyclically Adjusted Revenue per Share: ₹113.84 (As of Dec. 2025)


NSE:VIVIMEDLAB Vivimed Labs Ltd NSE:VIVIMEDLAB
40 GF Score
Price ₹5.40
GF Value ₹2.55
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Vivimed Labs Cyclically Adjusted Revenue per Share?

Vivimed Labs NSE:VIVIMEDLAB -3.40% 40 Cyclically Adjusted Revenue per Share is ₹113.84 as of Dec. 2025. GuruFocus rates NSE:VIVIMEDLAB with a GF Score™ of 40/100 and a GF Value™ of ₹2.55 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Vivimed Labs's adjusted revenue per share for the three months ended in Dec. 2025 was ₹1.932. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹113.84 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Vivimed Labs's average Cyclically Adjusted Revenue Growth Rate was -16.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -10.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Vivimed Labs was -7.30% per year. The lowest was -10.90% per year. And the median was -9.10% per year.

As of today (2026-07-09), Vivimed Labs's current stock price is ₹5.40. Vivimed Labs's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 was ₹113.84. Vivimed Labs's Cyclically Adjusted PS Ratio of today is 0.05.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vivimed Labs was 0.21. The lowest was 0.03. And the median was 0.05.


Vivimed Labs  (NSE:VIVIMEDLAB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Vivimed Labs's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=5.40/113.84
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vivimed Labs was 0.21. The lowest was 0.03. And the median was 0.05.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Vivimed Labs Cyclically Adjusted Revenue per Share Related Terms


Vivimed Labs Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Vivimed Labs's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivimed Labs Cyclically Adjusted Revenue per Share Chart

Vivimed Labs Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 190.83 181.65 167.44 151.38 129.17

Vivimed Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 136.60 129.17 124.62 120.14 113.84

NSE:VIVIMEDLAB vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vivimed Labs's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivimed Labs Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vivimed Labs's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vivimed Labs's Cyclically Adjusted PS Ratio falls into.


NSE:VIVIMEDLAB
40GF Score
Vivimed Labs Ltd NSE:VIVIMEDLAB
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivimed Labs Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vivimed Labs's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=1.932/163.2808*163.2808
=1.932

Current CPI (Dec. 2025) = 163.2808.

Vivimed Labs Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 42.849 102.518 68.246
201606 43.971 105.961 67.757
201609 35.779 105.961 55.134
201612 43.100 105.196 66.898
201703 52.287 105.196 81.158
201706 38.043 107.109 57.994
201709 34.457 109.021 51.606
201712 35.808 109.404 53.442
201803 28.393 109.786 42.228
201806 41.705 111.317 61.174
201809 42.291 115.142 59.972
201812 28.348 115.142 40.200
201903 34.547 118.202 47.722
201906 40.363 120.880 54.521
201909 33.917 123.175 44.960
201912 23.856 126.235 30.857
202003 17.731 124.705 23.216
202006 37.718 127.000 48.493
202009 26.702 130.118 33.507
202012 33.544 130.889 41.845
202103 4.698 131.771 5.821
202106 7.824 134.084 9.528
202109 6.558 135.847 7.882
202112 6.817 138.161 8.056
202203 7.286 138.822 8.570
202206 6.048 142.347 6.937
202209 5.340 144.661 6.027
202212 6.727 145.763 7.535
202303 3.990 146.865 4.436
202306 4.267 150.280 4.636
202309 4.061 151.492 4.377
202312 5.012 152.924 5.351
202403 4.148 153.035 4.426
202406 3.545 155.789 3.715
202409 2.987 157.882 3.089
202412 4.400 158.323 4.538
202503 2.755 157.552 2.855
202506 2.570 159.755 2.627
202509 2.484 162.289 2.499
202512 1.932 163.281 1.932

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹113.84 mean?
Vivimed Labs (NSE:VIVIMEDLAB) has a Cyclically Adjusted Revenue per Share of ₹113.84 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Vivimed Labs and its competitors.
Is Vivimed Labs' Cyclically Adjusted Revenue per Share too high?
Vivimed Labs' current Cyclically Adjusted Revenue per Share is ₹113.84. Overall, Vivimed Labs has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vivimed Labs' Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Vivimed Labs' Cyclically Adjusted Revenue per Share of ₹113.84 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Vivimed Labs and its competitors. Vivimed Labs's current Cyclically Adjusted Revenue per Share is ₹113.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivimed Labs stock overvalued right now?
Based on GuruFocus' analysis, Vivimed Labs (NSE:VIVIMEDLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.55, compared to a current price of ₹5.40 — trading 111.8% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹113.84. Vivimed Labs' overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Vivimed Labs (NSE:VIVIMEDLAB), the current Cyclically Adjusted Revenue per Share is ₹113.84 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vivimed Labs (NSE:VIVIMEDLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Vivimed Labs stock appears to be overvalued. The current stock price of ₹5.40 is trading 111.8% above its estimated GF Value™ of ₹2.55. GuruFocus considers Vivimed Labs to be Significantly Overvalued.

Key valuation signals for NSE:VIVIMEDLAB:

  • Cyclically Adjusted Revenue per Share: ₹113.84
  • GF Value™: ₹2.55 vs. price of ₹5.40 (111.8% above fair value)
  • GF Score™: 40/100 with 7 warning signs

No single metric tells the full story. See the NSE:VIVIMEDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vivimed Labs Business Description

Other Exchanges 532660:India
Address Green Lands, Beside The Plaza Hotel, D.No. 6-3-866/1/G1, 3rd & 4th Floor, GMR Towers, Begumpet, Hyderabad, TG, IND, 500016
Vivimed Labs Ltd is an India-based company that is engaged in the Business of Active pharmaceutical ingredients, Intermediates, Nutraceutical ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals, and Retail Branded Formulation manufacturing. The company has three reportable segments: the Speciality Chemicals Business, the Pharma Business, and others. The majority of revenue is earned through the Pharma business.
40GF Score

Get the complete analysis for NSE:VIVIMEDLAB

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹5.40
Price
₹2.55
GF Value